Marijuana.com

Hashishi

GW Pharma, Bayer get Canadian approval for cannabis-based Sativex in cancer pain
8-7-'07 | Hemscott

LONDON (Thomson Financial) - GW Pharmaceuticals PLC and Bayer AG's unit Bayer Inc said they have received Canadian regulatory conditional approval for Sativex, a cannabis-derived therapy, for advanced cancer pain treatment.

The approval has conditions attached to it, and UK-based AIM listed GW Pharmaceuticals said the approval reflects the 'promising nature of the clinical evidence which will be confirmed with further studies'.

Data from current studies show Sativex achieved a statistically significant improvement in pain relief, in comparison with placebo, the compnay said.

Sativex, the only pharmaceutical product derived from components of the cannabis plant, is administered through a spray pump under the tongue or on the inside of the cheek allowing a more flexible dosing than an oral tablet, GW added.

__________________
SWP



"I'm not into this detail stuff. I'm more concepty." -- "If I know the answer I'll tell you the answer, and if I don't, I'll just respond, cleverly." -- "Secretary Powell and I agree on every single issue that has ever been before this administration except for those instances where Colin's still learning." -- "As we know, there are known knowns; there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns: the ones we don't know we don't know."